公开(公告)号：WO2023034568A1

公开(公告)日：2023-03-09

申请号：PCT/US2022/042454

申请日：2022-09-02

申请人： YALE UNIVERSITY

发明人： SINHA, Rajita

IPC分类号： A61K31/045 ,  A61K31/352 ,  A61K31/05 ,  A61K31/33 ,  A61K31/335 ,  A61K31/35

摘要： In various aspects and embodiments the invention provides a method of treating pain, stress and anxiety in a subject in need thereof, wherein the method comprises administering to the subject in need thereof a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3:1 and about 6:1 CBD:THC.

公开(公告)号：WO2022120048A1

公开(公告)日：2022-06-09

申请号：PCT/US2021/061611

申请日：2021-12-02

申请人： UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

发明人： WIPF, Peter ,  HURYN, Donna M. ,  LAPORTE, Matthew G. ,  TERRAB, Leila ,  HOUGHTON, Michael James ,  TOPACIO, Andrea ,  MASKREY, Taber Sarah ,  KRISTUFEK, Tyler ,  SOZER, Uygar ,  CROCKER, Desirae Lynn ,  JOYASAWAL, Sipak ,  THORNTON, Alyssa ,  CHAUHAN, Shikha Singh ,  LIANG, Mary ,  IYER, Prema ,  PANDA, Jagannath

IPC分类号： C07C233/57 ,  A61K31/352 ,  A61K31/335 ,  C07D311/02

摘要： The present disclosure is directed to chromane compounds, chromane compounds demonstrating HDAC inhibition, and pharmaceutical compositions thereof. Additional embodiments include methods of using the chromane compounds. For example, the disclosure includes methods of inhibiting histone acetylation in a cell, comprising contacting the cell with a chromane compound of the disclosure. Additional embodiments include methods of treating a disease capable of treatment by inhibition of histone acetylation in a patient in need thereof, comprising administering a chromane compound of the disclosure.

公开(公告)号：WO2022006055A1

公开(公告)日：2022-01-06

申请号：PCT/US2021/039526

申请日：2021-06-29

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： SCHULMAN, Rebecca B. ,  JIA, Sisi ,  PHUA, Siew Cheng ,  NIHONGAKI, Yuta ,  LI, Yizeng ,  PACELLA, Michael ,  LI, Yi ,  MOHAMMED, Abdul Majeed ,  SUN, Sean X. ,  INOUE, Takanari

IPC分类号： A61K31/335 ,  A61K31/7088 ,  A61K38/12 ,  A61K38/02 ,  A61K38/14

摘要： Described are conjugates of nucleic acid nanotubes and cells by linking the nanotubes to a cell surface moiety. Devices, kits, systems, and methods comprising the nanotube cell conjugates are also described.

公开(公告)号：WO2021112242A1

公开(公告)日：2021-06-10

申请号：PCT/JP2020/045314

申请日：2020-12-04

申请人： 東興薬品工業株式会社 ,  Ｍｅｉｊｉ　Ｓｅｉｋａファルマ株式会社

发明人： 上下　泰造 ,  宮崎　隆 ,  田中　力 ,  大澤　福市

IPC分类号： A61K31/335 ,  A61K9/10 ,  A61K9/12 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/32 ,  A61P11/02 ,  A61P37/08 ,  A61P43/00

摘要： 本発明は、ステロイド化合物とオロパタジンを含有する組成物であって、ステロイド化合物が懸濁状態、オロパタジンが溶解状態で安定に存在する均一な組成物ならびにその製造方法に関する。

公开(公告)号：WO2021081117A2

公开(公告)日：2021-04-29

申请号：PCT/US2020/056700

申请日：2020-10-21

申请人： LABOMBARD, Denis, E.

发明人： LABOMBARD, Denis, E.

IPC分类号： A61F9/00 ,  A61F2/00 ,  A61L27/00 ,  A61K9/00 ,  A61K9/14 ,  A61K31/00 ,  A61K47/10 ,  A61K47/32 ,  A61F2/0095 ,  A61F2210/0004 ,  A61F2250/0004 ,  A61F2250/0068 ,  A61F9/0017 ,  A61K31/335 ,  A61K31/496 ,  A61K31/573 ,  A61K45/06 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/146 ,  C08L23/0853 ,  C08L23/12 ,  C08L71/02

摘要： An ocular device for placement under an eyelid that includes a plate with a back surface having at least one protrusion having a convex contact surface to contact the sclera of the eye and to provide an offset space. The plate can be connected to an elongated support member. The ocular device can deliver a material to an eye of a user, including, for example, a pharmaceutically active agent. A case for holding and dispensing an ocular device includes a well configured to retain fluid, a stabilizer, and a lid. The lid is connected to the well and rotatable between a position covering the well and a position with the well uncovered. The lid can have a port for adding fluid to the well, and a receiver, which can hold an ocular device, can project from the lid.

公开(公告)号：WO2020245832A1

公开(公告)日：2020-12-10

申请号：PCT/IL2020/050631

申请日：2020-06-04

申请人： RAMOT AT TEL-AVIV UNIVERSITY LTD. ,  THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER

发明人： ROCHKIND, Shimon

IPC分类号： A61L27/26 ,  A61L27/22 ,  A61L27/52 ,  A61L27/58 ,  A61K38/44 ,  A61P25/00 ,  A61K31/728 ,  A61K31/375 ,  A61K31/335 ,  A61K31/4045 ,  A61P43/00

摘要： Compositions and methods of using same for tissue regeneration are provided. Accordingly, there is provided a composition comprising a hyaluronic acid, a laminin polypeptide, an antioxidant and Copolymer 1 at a concentration range of 10 – 150 microgram/ ml. Also provided is a composition comprising a hyaluronic acid, a laminin polypeptide and vitamin E at a concentration range of 0.3 – 30 m M. Also provided are matrices and hydrogels of the compositions and methods of using same.

公开(公告)号：WO2020240266A1

公开(公告)日：2020-12-03

申请号：PCT/IB2019/054545

申请日：2019-05-31

申请人： CCMAR - CENTRO DE CIÊNCIAS DO MAR UNIVERSIDADE DO ALGARVE ,  INSTITUTO GULBENKIAN DE CIÊNCIA

发明人： CRISTIANO, Maria ,  CABRAL, Lília ,  LEITE, Ricardo ,  LEAL, José

IPC分类号： A61P33/02 ,  C07D323/04 ,  A61K31/335 ,  C07D491/113

摘要： The present invention relates to new endoperoxide compounds and compositions, and to a process for producing them for prophylaxis and control of perkinsiosis in bivalves. Endoperoxide compounds with biological activity against Perkinsus olseni include 13 trioxolanes and 9 tetraoxanes. Protozoan parasites of the genus Perkinsus are known to infect several species of marine molluscs worldwide, like oysters, abalones, clams, scallops, pearl oysters, cockles or mussels. The present invention also describes the synthesis of these compounds, in particular of new endoperoxide compounds of the tetraoxane family. Compositions comprising endoperoxide compounds are useful for prophylaxis and control of perkinsiosis in bivalves. Therefore, the present invention also relates to a method of controlling perkinsiosis in bivalves. The present invention is in the domain of aquaculture, medicine, pharmaceuticals and biochemistry.

公开(公告)号：WO2020185712A1

公开(公告)日：2020-09-17

申请号：PCT/US2020/021770

申请日：2020-03-09

申请人： ALAIRION, INC.

发明人： EDGAR, Dale M.

IPC分类号： A61K31/335 ,  A61P25/00 ,  C07D313/12

摘要： The present disclosure relates to methods of alleviating a symptom of, treating, or preventing a sleep disorder by administering a ligand of α2δ-1 auxiliary subunit of voltage-gated calcium channels, a ligand of α2δ-2 auxiliary subunit of voltage-gated calcium channels, a 5HT 2A receptor antagonist, a 5HT 2A receptor inverse agonist, a H 1 receptor antagonist, a H 1 receptor inverse agonist, a gamma-hydroxy butyrate (GHB) receptor ligand, or a GABA B receptor agonist, or pharmaceutically acceptable salts thereof, to a subject in need thereof.

公开(公告)号：WO2020147739A1

公开(公告)日：2020-07-23

申请号：PCT/CN2020/072186

申请日：2020-01-15

申请人： 武汉朗来科技发展有限公司 ,  武汉启瑞药业有限公司

发明人： 娄军 ,  陈永凯 ,  彭微 ,  张轶涵 ,  郭晓丹 ,  柳力 ,  刘军华 ,  钱丽娜 ,  王朝东

IPC分类号： C07D263/32 ,  C07D275/02 ,  C07D277/02 ,  C07D231/40 ,  C07D401/04 ,  A61K31/335 ,  A61K31/38 ,  A61K31/395 ,  A61P11/06 ,  A61P35/00

摘要： 本发明属于药物化学技术领域，具体涉及一种溶血磷脂酸受体拮抗剂及其制备方法。申请人惊奇地发现，本发明的化合物具有高的LPAR1拮抗活性和选择性，且毒性低、代谢稳定性好，具有良好的药物开发前景，可以用于预防或治疗与LPAR1相关的疾病或病症。申请人还意外地发现，本发明部分化合物的IC 50 值可以低至300nM以下，甚至50nM以下。并且，本发明的化合物都具有较好的安全性，其CC 50 范围可高达200μM以上。此外，本发明的化合物在人、大鼠、小鼠中都具有较好的代谢稳定性，这样优异的抑制活性对于它们作为LPAR1抑制剂应用于上述疾病或病症而言是令人非常期待的。此外，本发明化合物的制备方法简单，反应条件温和，产品收率高，适于工业化生产。

公开(公告)号：WO2020049591A1

公开(公告)日：2020-03-12

申请号：PCT/IN2019/050637

申请日：2019-09-05

申请人： NATIONAL CENTRE FOR CELL SCIENCE

发明人： SHASTRY, Padma

IPC分类号： A61K31/00 ,  A61K31/335 ,  A61K45/06 ,  A61K31/44

摘要： The present invention pertains to a synergistic combination comprising histone deacetylase inhibitors (HDACi) in combination with estrogen receptor (ER) antagonist for treating gliomas. The present invention also discloses composition containing the combination, and a method of use of the combination and the composition of the present invention and method of treatment using the combination.